Premium
Prostacyclin in Prostatic Cancer: A Better Marker than Bone Scan or Serum Acid Phosphatase?
Author(s) -
KHAN O.,
HENSBY C. N.,
WILLIAMS GORDON
Publication year - 1982
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1982.tb13506.x
Subject(s) - prostacyclin , cancer , acid phosphatase , medicine , bone resorption , endocrinology , carcinoma , chemistry , alpha (finance) , pathology , enzyme , biochemistry , surgery , construct validity , patient satisfaction
Summary— Prostaglandins have been implicated in the development and spread of malignant tumours. Gas chromatography and mass spectrometry (GC‐MS) analysis of prostaglandins in benign and malignant prostatic tissue showed that prostacyclin (PGI 2 ), a prostanoid known to induce bone resorption, was the major component. PGI2 is hydrolysed to 6‐oxo‐PGF 1a . Plasma levels of 6‐oxo‐PFG 1a were measured as an index of PGI 2 formation in patients with benign and malignant prostatic disease. The mean plasma 6‐oxo‐ level in an age‐matched control group was comparable to that of patients with benign prostatic hypertrophy. A significant elevation was found in patients with a TO carcinoma (P<0.05). Plasma 6‐oxo‐ levels rise with advancing disease and the concentration varied with the degree of tumour differentiation. Plasma 6‐oxo‐ levels were a more accurate monitor of disease progression than tartrate labile acid phosphatase in patients with M1 carcinoma. Persistently elevated levels were associated with a bad prognosis.